Abstract
PreviewDigitalis has long been used as an antiarrhythmic drug in treatment of paroxysmal supraventricular tachycardia, atrial fibrillation and flutter, and arrhythmias associated with congestive heart failure. However, newer evidence indicates that this cardiac glycoside has limited potency as an antiarrhythmic drug. In this review, the authors describe the effect of digitalis on cardiovascular function in management of atrial fibrillation and flutter. They conclude that while widespread use of digitalis as initial treatment for these supraventricular arrhythmias is justified by its low cost, ease of administration, and relatively few noncardiac side effects, newer drugs may ultimately prove more useful.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
